Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Down 41.9% in November

Adlai Nortye Ltd. (NASDAQ:ANL) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 2,500 shares, a decrease of 41.9% from the November 15th total of 4,300 shares. Based on an average daily volume of 15,200 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Price Performance

Shares of ANL stock traded up $0.09 on Friday, reaching $2.29. 567 shares of the company were exchanged, compared to its average volume of 11,586. Adlai Nortye has a one year low of $1.85 and a one year high of $17.48. The company has a 50-day moving average of $2.29 and a 200-day moving average of $3.02.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.